{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:29:41Z","timestamp":1793316581831,"version":"4.5.0"},"reference-count":201,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["1U01CA283931"],"award-info":[{"award-number":["1U01CA283931"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2021-SGR 01347"],"award-info":[{"award-number":["2021-SGR 01347"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["LCF\/PR\/SP23\/52950009"],"award-info":[{"award-number":["LCF\/PR\/SP23\/52950009"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","award":["NCI\/NIH P50 CA210964"],"award-info":[{"award-number":["NCI\/NIH P50 CA210964"]}],"id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2024-160007OB-I00"],"award-info":[{"award-number":["PID2024-160007OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2022-139365OB-I00"],"award-info":[{"award-number":["PID2022-139365OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["MICIU\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["MICIU\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018779","name":"Fundaci\u00f3n Fero","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001384","name":"Samuel Waxman Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001384","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022335","name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Universitat de Barcelona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022335","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["R01-CA265009"],"award-info":[{"award-number":["R01-CA265009"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["R01CA285544"],"award-info":[{"award-number":["R01CA285544"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["R01CA289041"],"award-info":[{"award-number":["R01CA289041"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["AG077921"],"award-info":[{"award-number":["AG077921"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["C9380\/A26813"],"award-info":[{"award-number":["C9380\/A26813"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["EPAEC246711CLIN"],"award-info":[{"award-number":["EPAEC246711CLIN"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["RSG-23-1151048-01-IBCD"],"award-info":[{"award-number":["RSG-23-1151048-01-IBCD"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA285580-01"],"award-info":[{"award-number":["R01-CA285580-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA292508-01A1"],"award-info":[{"award-number":["R01CA292508-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA082103"],"award-info":[{"award-number":["P30CA082103"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101077312"],"award-info":[{"award-number":["101077312"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011475","name":"Cholangiocarcinoma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011475","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["RA220126"],"award-info":[{"award-number":["RA220126"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cell.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:03:30Z","timestamp":1776351810000},"page":"2490-2514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Hallmarks of liver cancer: Therapeutic implications"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0547-2667","authenticated-orcid":false,"given":"Josep M.","family":"Llovet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Pinyol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Affo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Yarchoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Gores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin Kate","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Sia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2026.03.001_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cell.2026.03.001_bib2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.001_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.cell.2026.03.001_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.cell.2026.03.001_bib5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cell.2026.03.001_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.001_bib7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.001_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2025.12.049","article-title":"Hallmarks of cancer-Then and now, and beyond","author":"Hanahan","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.001_bib9","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","article-title":"Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis","volume":"75","author":"Pinyol","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib12","article-title":"Hepatocellular Carcinoma: Epidemiology, diagnosis and treatment","volume":"7","author":"Mauro","year":"2025","journal-title":"JHEP Rep."},{"key":"10.1016\/j.cell.2026.03.001_bib13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","article-title":"Molecular pathogenesis and systemic therapies for hepatocellular carcinoma","volume":"3","author":"Llovet","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cell.2026.03.001_bib14","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic Landscape and Biomarkers of Hepatocellular Carcinoma","volume":"149","author":"Zucman-Rossi","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cell.2026.03.001_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41575-020-0342-4","article-title":"Liver regeneration: biological and pathological mechanisms and implications","volume":"18","author":"Michalopoulos","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/j.gastro.2016.11.048","article-title":"Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis","volume":"152","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cell.2026.03.001_bib17","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2019.07.028","article-title":"An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents","volume":"157","author":"Moeini","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cell.2026.03.001_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/science.adv7129","article-title":"The origin of hepatocellular carcinoma depends on metabolic zonation","volume":"391","author":"Guo","year":"2026","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.001_bib19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41586-025-09733-1","article-title":"Hepatic zonation determines tumorigenic potential of mutant \u03b2-catenin","volume":"649","author":"Raven","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.001_bib20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nrclinonc.2015.103","article-title":"Advances in targeted therapies for hepatocellular carcinoma in the genomic era","volume":"12","author":"Llovet","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib21","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.001_bib22","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jhep.2020.11.052","article-title":"Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target","volume":"74","author":"Ningarhari","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jhep.2014.05.028","article-title":"TERT promoter mutations: Gatekeeper and driver of hepatocellular carcinoma","volume":"61","author":"Pinyol","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib24","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jhep.2024.06.037","article-title":"Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome","volume":"81","author":"Zoulim","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib25","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.001_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1688460","article-title":"Comprehensive Landscape of ARID Family Members and Their Association with Prognosis and Tumor Microenvironment in Hepatocellular Carcinoma","volume":"2022","author":"Sun","year":"2022","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.cell.2026.03.001_bib27","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/0008-5472.CAN-08-0742","article-title":"Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma","volume":"68","author":"Chiang","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2026.03.001_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.001_bib29","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.1158\/1078-0432.CCR-20-1497","article-title":"Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma","volume":"26","author":"Bassaganyas","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.001_bib30","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.celrep.2015.02.027","article-title":"YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression","volume":"10","author":"Fitamant","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.cell.2026.03.001_bib31","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.cell.2006.05.030","article-title":"Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach","volume":"125","author":"Zender","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.001_bib32","doi-asserted-by":"crossref","first-page":"8212","DOI":"10.1073\/pnas.1206062109","article-title":"A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions","volume":"109","author":"Xue","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2026.03.001_bib33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature17157","article-title":"Deletions linked to TP53 loss drive cancer through p53-independent mechanisms","volume":"531","author":"Liu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.001_bib34","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1096\/fj.00-0487fje","article-title":"Lack of p53 accelerates hepatocarcinogenesis in transgenic mice constitutively overexpressing c-myc in the liver","volume":"15","author":"Klocke","year":"2001","journal-title":"FASEB J."},{"key":"10.1016\/j.cell.2026.03.001_bib35","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.80854","article-title":"MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer","volume":"12","author":"Zhu","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.cell.2026.03.001_bib36","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1172\/JCI31457","article-title":"Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma","volume":"117","author":"Calvisi","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cell.2026.03.001_bib37","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ng.2256","article-title":"Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma","volume":"44","author":"Guichard","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cell.2026.03.001_bib38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cell.2014.01.066","article-title":"Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor \u03b2 signaling","volume":"157","author":"Weissmueller","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.cell.2026.03.001_bib39","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/gutjnl-2021-325405","article-title":"Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer","volume":"71","author":"Revia","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cell.2026.03.001_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2025-336317","article-title":"Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications","author":"Bueloni","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.cell.2026.03.001_bib41","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s41586-025-08585-z","article-title":"Human-correlated genetic models identify precision therapy for liver cancer","volume":"639","author":"M\u00fcller","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.001_bib42","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cell.2026.03.001_bib43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.cell.2026.03.001_bib44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib45","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41575-024-01024-w","article-title":"Precision models in hepatocellular carcinoma","volume":"22","author":"Barcena-Varela","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib46","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.001_bib47","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02383-5","article-title":"A first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors","volume":"41","author":"Chan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.001_bib48","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/gutjnl-2016-312268","article-title":"Palbociclib (PD-0332991), a selective CDK4\/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma","volume":"66","author":"Bollard","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cell.2026.03.001_bib49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jhep.2025.02.039","article-title":"Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis","volume":"83","author":"de Zawadzki","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib50","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1078-0432.CCR-18-1254","article-title":"The Role of Angiogenesis in Hepatocellular Carcinoma","volume":"25","author":"Morse","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.001_bib51","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.001_bib52","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cell.2026.03.001_bib53","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.001_bib54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.001_bib55","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.001_bib56","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.001_bib57","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.783236","article-title":"Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma","volume":"12","author":"Xing","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cell.2026.03.001_bib59","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.001_bib60","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2026.03.001_bib61","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1158\/1078-0432.CCR-11-2322","article-title":"Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib","volume":"18","author":"Lachenmayer","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.001_bib62","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1158\/1078-0432.CCR-18-3778","article-title":"Immune Exclusion-Wnt\/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC","volume":"25","author":"Pinyol","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.001_bib63","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-Catenin Activation Promotes Immune Escape and Resistance to Anti\u2013PD-1 Therapy in Hepatocellular Carcinoma","volume":"9","author":"Ruiz de Galarreta","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.001_bib64","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41588-025-02496-5","article-title":"Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling","volume":"58","author":"Krishna","year":"2026","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cell.2026.03.001_bib65","series-title":"WNTinib is a Multi-Kinase Inhibitor with Specificity Against \u03b2-Catenin Mutant Hepatocellular Carcinoma","author":"Rialdi","year":"2023"},{"key":"10.1016\/j.cell.2026.03.001_bib66","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1158\/1078-0432.CCR-25-0725","article-title":"E7386 enhances lenvatinib\u2019s antitumor activity in preclinical models and human hepatocellular carcinoma","volume":"31","author":"Mesropian","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.001_bib67","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.bbadis.2013.06.001","article-title":"Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis","volume":"1832","author":"Nevzorova","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cell.2026.03.001_bib68","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jhep.2020.01.019","article-title":"The landscape of gene mutations in cirrhosis and hepatocellular carcinoma","volume":"72","author":"M\u00fcller","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib69","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.001_bib70","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.001_bib71","doi-asserted-by":"crossref","first-page":"E5900","DOI":"10.1073\/pnas.1706559114","article-title":"Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses","volume":"114","author":"Chew","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2026.03.001_bib72","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.cell.2026.03.001_bib73","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jhep.2024.12.016","article-title":"Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma","volume":"82","author":"Cappuyns","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib74","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41575-025-01127-y","article-title":"WNT\u2013\u03b2-catenin signalling in hepatocellular carcinoma: from bench to clinical trials","volume":"23","author":"Lehrich","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib75","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib76","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.001_bib77","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.001_bib78","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.001_bib79","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib80","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity","volume":"2","author":"Ho","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cell.2026.03.001_bib81","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib82","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib83","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(25)01720-9","article-title":"Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2\/3 trial","volume":"406","author":"Wang","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.001_bib84","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.001_bib85","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.001_bib86","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib87","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1080\/14796694.2024.2355863","article-title":"IMbrave152\/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma","volume":"20","author":"Badhrinarayanan","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib88","unstructured":"ClinicalTrials.gov (2025). Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma (ARTEMIDE-HCC01). https:\/\/clinicaltrials.gov\/study\/NCT06921785."},{"key":"10.1016\/j.cell.2026.03.001_bib89","article-title":"Phase 2\/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma","volume":"42","author":"Abou-Alfa","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib90","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2026.03.001_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2279","article-title":"LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)","volume":"35","author":"Yopp","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib92","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2026.03.001_bib93","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jhep.2025.07.033","article-title":"Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma","volume":"84","author":"Meyer","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib94","article-title":"Phase I study of C-CAR031, a GPC3-specific TGF\u03b2RIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib95","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","article-title":"Oncolytic virus VG161 in refractory hepatocellular carcinoma","volume":"641","author":"Shen","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.001_bib96","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2026.03.001_bib97","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cell.2026.03.001_bib98","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","article-title":"Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies","volume":"67","author":"Bruix","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib99","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1053\/j.gastro.2019.01.261","article-title":"Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma","volume":"156","author":"Teufel","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cell.2026.03.001_bib100","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib101","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/j.gastro.2022.09.005","article-title":"Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma","volume":"164","author":"Haber","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cell.2026.03.001_bib102","series-title":"Liver Imaging Reporting and Data System (LI-RADS\u00ae) v2018 Core","year":"2018"},{"key":"10.1016\/j.cell.2026.03.001_bib103","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41388-020-01519-1","article-title":"Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma","volume":"40","author":"von Felden","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.cell.2026.03.001_bib104","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2025.04.017","article-title":"Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma","volume":"83","author":"Vithayathil","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib105","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00261-021-03386-0","article-title":"Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC","volume":"47","author":"Lewis","year":"2022","journal-title":"Abdom. Radiol."},{"key":"10.1016\/j.cell.2026.03.001_bib106","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41571-023-00731-8","article-title":"Exploring a new pathway for biomarker-based approval of immunotherapies","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib107","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","article-title":"Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis","volume":"25","author":"D'Alessio","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib108","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O'Dwyer","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2026.03.001_bib109","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/liv.14094","article-title":"Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma","volume":"39","author":"Vicent","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.cell.2026.03.001_bib111","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1172\/JCI63212","article-title":"Cholangiocarcinomas can originate from hepatocytes in mice","volume":"122","author":"Fan","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cell.2026.03.001_bib112","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1053\/j.gastro.2024.05.033","article-title":"Human Hepatocytes Can Give Rise to Intrahepatic Cholangiocarcinomas","volume":"167","author":"Hsu","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cell.2026.03.001_bib113","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib114","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cell.2026.03.001_bib115","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/oncolo\/oyac150","article-title":"Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017","volume":"27","author":"Javle","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.cell.2026.03.001_bib116","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib117","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib118","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in Western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib119","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.cell.2026.03.001_bib120","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2026.03.001_bib121","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib122","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cell.2026.03.001_bib123","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ajpath.2024.11.005","article-title":"Cholangiocarcinoma Targeted Therapies: Mechanisms of Action and Resistance","volume":"195","author":"Ellis","year":"2025","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cell.2026.03.001_bib124","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.001_bib126","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib127","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.001_bib128","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cell.2026.03.001_bib129","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004135","article-title":"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma","volume":"10","author":"Borad","year":"2014","journal-title":"PLoS Genet."},{"key":"10.1016\/j.cell.2026.03.001_bib130","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-022-05066-5","article-title":"Truncated FGFR2 is a clinically actionable oncogene in multiple cancers","volume":"608","author":"Zingg","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.001_bib131","article-title":"Cell of origin in biliary tract cancers and clinical implications","volume":"3","author":"Moeini","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.cell.2026.03.001_bib132","first-page":"306","article-title":"The cyclin-dependent kinase pathway involving CDK1 is a potential therapeutic target for cholangiocarcinoma","volume":"43","author":"Yamamura","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cell.2026.03.001_bib133","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.174220","article-title":"CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon","volume":"9","author":"Zhu","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.cell.2026.03.001_bib134","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib135","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41379-020-00656-y","article-title":"Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinoma","volume":"34","author":"Guedj","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.cell.2026.03.001_bib136","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3892\/or_00000309","article-title":"Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma","volume":"21","author":"Thuwajit","year":"2009","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cell.2026.03.001_bib137","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jss.2016.03.044","article-title":"Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma","volume":"203","author":"Bergeat","year":"2016","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.cell.2026.03.001_bib138","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","article-title":"Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations","volume":"39","author":"Affo","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.001_bib139","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jhep.2020.05.039","article-title":"Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma","volume":"73","author":"Zhang","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib140","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib141","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.001_bib142","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.001_bib143","doi-asserted-by":"crossref","DOI":"10.1172\/JCI182417","article-title":"Identification of potent biparatopic antibodies targeting FGFR2 fusion-driven cholangiocarcinoma","volume":"135","author":"Chaturantabut","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cell.2026.03.001_bib144","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib145","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib146","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.001_bib147","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/hep.32424","article-title":"Biology of IDH mutant cholangiocarcinoma","volume":"75","author":"Wu","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cell.2026.03.001_bib148","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib149","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.cell.2026.03.001_bib150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41416-018-0199-2","article-title":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","volume":"120","author":"Goeppert","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cell.2026.03.001_bib151","first-page":"604","article-title":"Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma","volume":"49","author":"Isa","year":"2002","journal-title":"Hepatogastroenterology."},{"key":"10.1016\/j.cell.2026.03.001_bib152","doi-asserted-by":"crossref","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib153","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.001_bib154","article-title":"The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2026.03.001_bib155","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.001_bib156","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.001_bib157","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cell.2026.03.001_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.cell.2026.03.001_bib159","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.31092","article-title":"Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cell.2026.03.001_bib160","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","article-title":"Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications","volume":"72","author":"Martin-Serrano","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.cell.2026.03.001_bib161","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hep.32150","article-title":"The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma","volume":"75","author":"Carapeto","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cell.2026.03.001_bib162","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/PO.20.00150","article-title":"Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade","volume":"4","author":"Arf\u00e8","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib163","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib164","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1093\/oncolo\/oyab073","article-title":"A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma","volume":"27","author":"Monge","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.cell.2026.03.001_bib165","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1172\/JCI137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cell.2026.03.001_bib166","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/cam4.4593","article-title":"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer","volume":"11","author":"Doki","year":"2022","journal-title":"Cancer Med."},{"key":"10.1016\/j.cell.2026.03.001_bib167","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cell.2026.03.001_bib168","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccell.2019.08.007","article-title":"Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer","volume":"36","author":"Ma","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.001_bib169","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jhep.2021.06.028","article-title":"Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"75","author":"Ma","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib170","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3892\/or.2016.4807","article-title":"Aberrant expression of B7-H4 correlates with poor prognosis and suppresses tumor-infiltration of CD8+ T lymphocytes in human cholangiocarcinoma","volume":"36","author":"Zhao","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cell.2026.03.001_bib171","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-017-0015-6","article-title":"Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma","volume":"8","author":"Xie","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cell.2026.03.001_bib172","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/apm.12837","article-title":"B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma","volume":"126","author":"Cheng","year":"2018","journal-title":"APMIS"},{"key":"10.1016\/j.cell.2026.03.001_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115229","article-title":"The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity","volume":"44","author":"Sibai","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.cell.2026.03.001_bib174","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cell.2026.03.001_bib175","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/PAS.0000000000000670","article-title":"Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma","volume":"40","author":"Hayashi","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.cell.2026.03.001_bib176","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.001_bib177","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1158\/2326-6066.CIR-21-1101","article-title":"Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing-Assisted Multiomics Analysis","volume":"10","author":"Bao","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cell.2026.03.001_bib178","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/hep.26577","article-title":"Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma","volume":"58","author":"Sulpice","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cell.2026.03.001_bib179","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.001_bib180","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/HEP.0000000000001283","article-title":"Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma","volume":"83","author":"Hong","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cell.2026.03.001_bib181","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-21-1157","article-title":"Multiomic Analysis Reveals Comprehensive Tumor Heterogeneity and Distinct Immune Subtypes in Multifocal Intrahepatic Cholangiocarcinoma","volume":"28","author":"Chen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2026.03.001_bib182","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000632","article-title":"Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging","volume":"9","author":"Baretti","year":"2025","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.cell.2026.03.001_bib183","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-21-1077","article-title":"Mutant IDH Inhibits IFN\u03b3-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2026.03.001_bib184","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cell.2026.03.001_bib185","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/0008-5472.CAN-12-2130","article-title":"Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma","volume":"73","author":"Mertens","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2026.03.001_bib186","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41392-025-02347-z","article-title":"NADPH oxidase 1\/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts","volume":"10","author":"Amengual","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cell.2026.03.001_bib187","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.001_bib188","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1158\/0008-5472.CAN-18-3060","article-title":"Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy","volume":"79","author":"Clift","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2026.03.001_bib189","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/1535-7163.MCT-10-0470","article-title":"Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models","volume":"9","author":"Thompson","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cell.2026.03.001_bib190","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib191","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ccell.2025.05.017","article-title":"Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma","volume":"43","author":"Huang","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.001_bib192","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jhep.2022.01.014","article-title":"Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma","volume":"76","author":"Calderaro","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cell.2026.03.001_bib193","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S1470-2045(23)00468-0","article-title":"Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study","volume":"24","author":"Zeng","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cell.2026.03.001_bib194","article-title":"Artificial intelligence predicts outcome-related molecular profiles and vascular invasion in hepatocellular carcinoma","volume":"7","author":"Seraphin","year":"2025","journal-title":"JHEP Rep."},{"key":"10.1016\/j.cell.2026.03.001_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105520","article-title":"Survival prediction on intrahepatic cholangiocarcinoma with histomorphological analysis on the whole slide images","volume":"146","author":"Xie","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.cell.2026.03.001_bib196","first-page":"40","article-title":"Immune checkpoint B7-H4 promotes cholangiocarcinoma growth via TGFb-induced stromal remodelling, unveleing a novel targetable tumor-stroma axis","volume":"80","author":"Bramel","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cell.2026.03.001_bib197","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ccr.2012.02.007","article-title":"Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4","volume":"21","author":"Dapito","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2026.03.001_bib198","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1158\/0008-5472.CAN-21-1407","article-title":"Translating the Science of Cancer Dormancy to the Clinic","volume":"81","author":"Aguirre-Ghiso","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2026.03.001_bib199","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41573-024-01017-z","article-title":"Targeting the peripheral neural-tumour microenvironment for cancer therapy","volume":"23","author":"Yaniv","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2026.03.001_bib200","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2026.03.001_bib201","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN Guidelines\u00ae Insights: Biliary Tract Cancers, Version 2.2023","volume":"21","author":"Benson","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867426002680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867426002680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T12:33:41Z","timestamp":1779539621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867426002680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":201,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0092867426002680"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2026.03.001","relation":{},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hallmarks of liver cancer: Therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}